Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  


Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
NIH Change to annual progress reports received on/after 10/1/14

National Institutes of Health (NIH) annual progress reports received on or after October 1, 2014 must include a section to describe how individual development plans (IDPs) are used to identify and promote the career goals of graduate students and postdoctoral researchers associated with the award.

See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-113.html.

 
Avoiding Problems with Suspension and Debarment

Federal regulations require Case Western Reserve University to conduct business only with vendors, subcontractors, subawardees and individuals who are in good standing with the federal government. Anyone who is not in good standing with federal agencies cannot work on or provide services for government grants or contracts. People and entities who are subject to these restrictions are generally described as having been "debarred," "suspended" or "excluded."

To avoid inadvertent problems, visit http://www.sam.gov and verify that study staff, collaborators and vendors are not debarred, suspended or otherwise ineligible to receive federal funds.

 
Pilot Grants Available from CGREAL

The Center for Genetic Research Ethics and Law (CGREAL) is currently accepting applications for pilot projects from Case Western Reserve University and Cleveland Clinic faculty who are interested in developing research on:

  • Ethical, legal, and social issues (ELSI) in the design and conduct of human genetic research, or
  • The translation of research results into clinical medicine, public health, and health policy needs related to genetics.
These grants are designed to support exploratory efforts towards the development of larger scholarly projects or lines of research related to CGREAL’s mission to facilitate interdisciplinary inquiry into the ethical, legal, and social implications of new advances in genetic and genomic science.

Criteria for evaluation will focus on the potential for expanding and enriching the range of perspectives being brought to genetic research ethics and law at CGREAL. Preference will be given to projects that are deemed likely to foster further collaborative research opportunities.

Requests may be made for up to $5,000. Funds may not be used for faculty salary support. Applications are encouraged from Case Western University and Cleveland Clinic faculty at any rank/level.

Applications will be accepted on a rolling basis and funding for awarded seed grants will be available immediately upon project approval.

Interested faculty should contact Aaron Goldenberg (aaron.goldenberg@case.edu or 216-368-8729).

For further information on the Center for Genetic Research Ethics and Law, see http://www.case.edu/med/bioethics/cgreal/ .

 
The Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

For further information, contact Kim Volarcik at (216) 368-0134 or kav6@case.edu.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.